Compare DexCom, Inc. (DXCM) vs Modine Manufacturing Company (MOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Modine Manufacturing Company — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.81B), while Modine Manufacturing Company trades at $184.22 (market cap $9.66B). The key difference: DexCom, Inc. is far larger — about 3.3× Modine Manufacturing Company's market cap, and DexCom, Inc. is trading nearer its 52-week high, Modine Manufacturing Company nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Modine Manufacturing Company for 33 Days on average.
| DXCM | MOD | |
|---|---|---|
Market Cap | $31.81B | $9.66B |
Volume | 2,861,821 | 1,331,946 |
Sector | Health | Industrials |
52-Week High | $92.34 | $283.95 |
52-Week Low | $54.84 | $110.73 |
Typical Hold Time | 62 Days | 33 Days |
Enterprise Value | $31.26B | $10.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
Modine Manufacturing (MOD) trades at $189.44, down 0.25% on the day, with a neutral technical signal and key support at $184. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.53 exceeding the $1.30 forecast. Recent corporate actions include the completion of a $946.4 million spin-off of its Performance Technologies unit with Gentherm, potentially reshaping its business focus toward thermal management solutions.
The outlook remains supported by strong analyst sentiment with a $331.25 consensus price target and 77% buy ratings, but risks include a high P/E ratio of 67.87 and a projected decline in net profit margin to 4.27% for 2026. The stock offers growth potential from its data center cooling expansion but faces execution risks post-spin-off and competitive pressures in the auto parts sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →
